

Palladium(II)-Catalyzed Intermolecular Oxidative C-3 Alkenylations of Imidazo[1,2-a] pyridines by Substrate-Contolled Regioselective C-H Functionalization

Hua Cao,* Sai Lei, Jinqiang Liao, Jianping Huang, Huifang Qiu, Qinlin Chen,
Shuxian Qiu and Yaoyi Chen

*^aSchool of Chemistry and Chemical Engineering, Guangdong Pharmaceutical
University, Guangzhou 510006, P.R. of China;*

^bBASF Catalyst, 23800 mercantile road, beachwood, ohio, 44124

E-mail: caohua@gdpu.edu.cn,

Supporting Information

List of Contents

A. General method.....	2
B. General Procedure.....	2
C. Analytical data	3

A. General method

All reactions were performed for synthesis of products at 120 °C in a round bottom flask equipped with magnetic stir bar. All the chemicals were purchased from Alfa Aesar and Acros Chemical, and used without further purification. NMR spectra were recorded using a Bruker Avance 400 MHz NMR spectrometer (100 M Hz for carbon) and respectively referenced to 7.26 and 77.0 ppm for chloroform-d solvent with TMS as internal standard. Mass spectra were recorded on a Shimadzu GCMS–QP5050A at an ionization voltage of 70eV equipped with a DB–WAX capillary column (internal diameter = 0.25 mm, length = 30 m). IR spectra were obtained as potassium bromide pellets or as liquid films between two potassium bromide pellets with a Bruker Vector 22 spectrometer. TLC was performed using commercially prepared 100-400 mesh silica gel plates (GF₂₅₄), and visualization was effected at 254 nm.

B. General Procedure

Synthesis of 3a according to the following procedure:

2-methylimidazo[1,2-a]pyridine (**1a** 0.5 mmol), styrene (**2a** 2.5 mmol), 5 mol% Pd(OAc)₂, 5 mol% AgCO₃, AcOH (0.5 mol) and Ac₂O (0.5 mol) were added in dioxane (3 mL) at room temperature. And then the mixture was stirred at 120 °C under oxygen atmosphere (with oxygen balloon 500 mL) for 24 h. After completion of the reaction, water (8 mL) was added. The aqueous solution was extracted with diethyl ether (3×15 mL), and the combined extract was dried with anhydrous MgSO₄. Solvent was removed, and the crude product was separated by column chromatography (eluted with petroleum ether : ethyl acetate=2:1) to give a pure sample of **4a**.

General procedure for the synthesis of 4a:

2-methylimidazo[1,2-a]pyridine (**1a** 0.5 mmol), butyl acrylate (**2a** 2.5 mmol), 5 mol% Pd(OAc)₂, 5 mol% AgCO₃, AcOH (0.5 mol) and Ac₂O (0.5 mol) were added in dioxane (3 mL) at room temperature. And then the mixture was stirred at 120 °C under oxygen atmosphere (with

oxygen balloon 500 mL) for 24 h. After completion of the reaction, water (8 mL) was added. The aqueous solution was extracted with diethyl ether (3×15 mL), and the combined extract was dried with anhydrous MgSO₄. Solvent was removed, and the crude product was separated by column chromatography (eluted with petroleum ether: ethyl acetate=2:1) to give a pure sample of **3a**.

C. Analytical data

3-(1-phenylvinyl)imidazo[1,2-a]pyridine(3a): ¹H NMR (400 MHz, CDCl₃): δ 7.74 (d, *J* = 7.6 Hz, 2H), 7.62 (d, *J* = 6.8 Hz, 1H), 7.28-7.36 (m, 5H), 7.21 (t, *J* = 8.0 Hz, 1H), 6.69 (t, *J* = 6.8 Hz, 1H), 5.77 (s, 1H), 5.61 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 138.2, 137.2, 133.5, 128.9, 128.7, 127.0, 125.1, 117.7, 117.6, 112.5. ESI-MS *m/z* (%) 201 (100) [M+H]⁺. Anal. Calcd for C₁₅H₁₂N₂: C, 69.74; H, 7.02; N, 12.72; Found: C, 81.66; H, 5.45; N, 12.81;

7-methyl-3-(1-phenylvinyl)imidazo[1,2-a]pyridine(3b): ¹H NMR (400 MHz, CDCl₃): δ 7.64 (s, 1H), 7.48 (d, *J* = 6.8 Hz, 2H), 7.28-7.35 (m, 5H), 6.51 (t, *J* = 6.8 Hz, 1H), 5.72 (s, 1H), 5.58 (s, 1H), 2.37 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 146.4, 138.3, 137.3, 133.0, 128.8, 128.6, 127.0, 124.3, 117.0, 116.6, 115.2, 21.2. ESI-MS *m/z* (%) 235 (100) [M+H]⁺. Anal. Calcd for C₁₆H₁₄N₂: C, 82.02; H, 6.02; N, 11.96; Found: C, 82.10; H, 6.00; N, 11.91;

8-methyl-3-(1-phenylvinyl)imidazo[1,2-a]pyridine(3c): ¹H NMR (400 MHz, CDCl₃): δ 7.69 (s, 1H), 7.49 (d, *J* = 6.8 Hz, 1H), 7.28-7.35 (m, 5H), 6.96 (d, *J* = 6.8 Hz, 1H), 6.57 (d, *J* = 6.8 Hz, 1H), 5.74 (s, 1H), 5.59 (s, 1H), 2.64 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 138.5, 137.7, 133.4, 128.8, 128.6, 128.5, 127.6, 127.0, 123.1, 122.9, 117.7, 112.2, 17.0. ESI-MS *m/z* (%) 235 (100) [M+H]⁺. Anal. Calcd for C₁₆H₁₄N₂: C, 82.02; H, 6.02; N, 11.96; Found: C, 82.12; H, 5.99; N, 11.69;

6-methyl-3-(1-phenylvinyl)imidazo[1,2-a]pyridine(3d): ¹H NMR (400 MHz, CDCl₃): δ 7.67 (d, *J* = 8.8 Hz, 2H), 7.42 (s, 1H), 7.29-7.36 (m, 5H), 7.04 (d, *J* = 8.0 Hz, 1H), 5.77 (s, 1H), 5.59 (s, 1H), 2.17 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 138.5, 137.3, 133.1, 128.8, 128.6, 128.1, 127.0, 122.7, 117.7, 117.0, 18.3. ESI-MS *m/z* (%) 235 (100) [M+H]⁺. Anal. Calcd for C₁₆H₁₄N₂: C, 82.02; H, 6.02; N, 11.96; Found: C, 82.09; H, 6.05; N, 11.92;

3-(1-(4-fluorophenyl)vinyl)imidazo[1,2-a]pyridine(3e): ¹H NMR (400 MHz, CDCl₃): δ 7.70 (s, 1H), 7.64 (d, *J* = 7.2 Hz, 1H), 7.18-7.31 (m, 4H), 7.02-7.06 (m, 2H), 6.72 (t, *J* = 6.8 Hz, 1H), 5.72 (s, 1H), 5.60 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 164.2 (*J* = 247.1 Hz), 148.8, 136.2, 134.3, 131.2, 129.5, 128.8, 128.7, 125.0, 117.7 (*J* = 49.1 Hz), 116.0, 115.6 (*J* = 43.6 Hz), 112.7. ESI-MS *m/z* (%) 239 (100) [M+H]⁺. Anal. Calcd for C₁₅H₁₁FN₂: C, 75.62; H, 4.65; N, 11.76; Found: C, 75.53; H, 4.67; N, 11.71;

3-(1-(4-fluorophenyl)vinyl)-7-methylimidazo[1,2-a]pyridine(3f): ¹H NMR (400 MHz, CDCl₃): δ 7.60 (s, 1H), 7.51 (d, *J* = 7.2 Hz, 1H), 7.41 (s, 1H), 7.28-7.31 (m, 2H), 7.01-7.06 (m, 2H), 6.51 (d, *J* = 7.2 Hz, 1H), 5.64 (s, 1H), 5.55 (s, 1H), 2.37 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 164.2 (*J* = 246.9

Hz), 136.5, 135.5, 134.7, 133.9, 129.9, 129.8, 128.9, 128.8, 124.1, 116.3, 115.8, 115.0, 21.2. ESI-MS m/z (%) 253 (100) $[M+H]^+$. Anal. Calcd for $C_{16}H_{13}FN_2$: C, 76.17; H, 5.19; N, 11.10; Found: C, 76.29; H, 5.16; N, 11.05;

3-(1-(4-fluorophenyl)vinyl)-8-methylimidazo[1,2-a]pyridine(3g): 1H NMR (400 MHz, $CDCl_3$): δ 7.67 (s, 1H), 7.51 (d, $J = 7.2$ Hz, 1H), 7.25-7.28 (m, 2H), 6.96-7.04 (m, 3H), 6.60 (t, $J = 7.2$ Hz, 1H), 5.68 (s, 1H), 5.57 (s, 1H), 2.64 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 164.2 ($J = 246.7$ Hz), 146.7, 136.6, 133.5, 129.9, 128.8, 128.7, 127.7, 123.2, 122.8, 116.7, 115.8, 112.3, 17.0. ESI-MS m/z (%) 253 (100) $[M+H]^+$. Anal. Calcd for $C_{16}H_{13}FN_2$: C, 76.17; H, 5.19; N, 11.10; Found: C, 76.26; H, 5.21; N, 11.06;

3-(1-(4-fluorophenyl)vinyl)-6-methylimidazo[1,2-a]pyridine(3h): 1H NMR (400 MHz, $CDCl_3$): δ 7.60 (d, $J = 6.8$ Hz, 1H), 7.56 (s, 1H), 7.44 (s, 1H), 7.27-7.30 (m, 2H), 7.01-7.05 (m, 3H), 5.69 (s, 1H), 5.56 (s, 1H), 2.19 (s, 3H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 164.2 ($J = 246.7$ Hz), 145.4, 136.5, 134.7, 133.9, 131.2, 128.8, 128.7, 127.7, 124.4, 122.5, 122.0, 117.2, 116.6, 115.8, 18.3. ESI-MS m/z (%) 253 (100) $[M+H]^+$. Anal. Calcd for $C_{16}H_{13}FN_2$: C, 76.17; H, 5.19; N, 11.10; Found: C, 76.29; H, 5.17; N, 11.05;

3-(1-(4-tert-butylphenyl)vinyl)imidazo[1,2-a]pyridine(3i): 1H NMR (400 MHz, $CDCl_3$): δ 7.67-7.71 (m, 3H), 7.35 (d, $J = 8.4$ Hz, 2H), 7.16-7.24 (m, 3H), 6.70 (t, $J = 6.8$ Hz, 1H), 5.77 (s, 1H), 5.56 (s, 1H), 1.32 (s, 9H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 151.9, 137.0, 135.2, 128.6, 126.6, 125.7, 125.2, 117.7, 116.7, 112.3, 34.6, 31.29. ESI-MS m/z (%) 277 (100) $[M+H]^+$. Anal. Calcd for $C_{19}H_{20}N_2$: C, 82.57; H, 7.29; N, 10.14; Found: C, 82.46; H, 7.32; N, 10.20;

3-(1-(4-tert-butylphenyl)vinyl)-7-methylimidazo[1,2-a]pyridine(3j): 1H NMR (400 MHz, $CDCl_3$): δ 7.62 (s, 1H), 7.55 (d, $J = 7.2$ Hz, 1H), 7.42 (s, 1H), 7.34 (d, $J = 8.4$ Hz, 2H), 7.24 (d, $J = 8.4$ Hz, 2H), 6.48 (d, $J = 6.8$ Hz, 1H), 5.70 (s, 1H), 5.52 (s, 1H), 2.37 (s, 3H), 1.33 (s, 9H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 151.8, 137.2, 135.5, 135.3, 133.6, 126.7, 125.7, 124.3, 116.2, 116.0, 114.8, 34.6, 31.3, 21.2. ESI-MS m/z (%) 291 (100) $[M+H]^+$. Anal. Calcd for $C_{20}H_{22}N_2$: C, 82.72; H, 7.64; N, 9.65; Found: C, 82.61; H, 7.67; N, 9.71;

3-(1-(4-tert-butylphenyl)vinyl)-5-methylimidazo[1,2-a]pyridine(4k): 1H NMR (400 MHz, $CDCl_3$): δ 7.68 (s, 1H), 7.55 (d, $J = 6.8$ Hz, 1H), 7.35 (d, $J = 8.4$ Hz, 2H), 7.24 (d, $J = 8.4$ Hz, 2H), 6.57 (d, $J = 6.8$ Hz, 1H), 5.73 (s, 1H), 5.53 (s, 1H), 2.64 (s, 3H), 1.32 (s, 9H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 151.7, 137.3, 135.5, 133.4, 127.6, 126.7, 125.7, 123.0, 116.4, 112.1, 34.6, 31.3, 17.0. ESI-MS m/z (%) 291 (100) $[M+H]^+$. Anal. Calcd for $C_{20}H_{22}N_2$: C, 82.72; H, 7.64; N, 9.65; Found: C, 82.63; H, 7.62; N, 9.70;

3-(1-(4-chlorophenyl)vinyl)imidazo[1,2-a]pyridine(3l): 1H NMR (400 MHz, $CDCl_3$): δ 7.68 (s, 1H), 7.62 (d, $J = 7.2$ Hz, 1H), 7.33 (d, $J = 8.8$ Hz, 2H), 7.15-7.25 (m, 4H), 6.69 (t, $J = 6.8$ Hz, 1H), 5.73 (s, 1H), 5.61 (s, 1H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 146.4, 136.9, 136.4, 134.3, 129.4, 129.0, 128.8, 128.3, 124.8, 124.4, 118.0, 117.4, 112.4. ESI-MS m/z (%) 255 (100) $[M+H]^+$. Anal. Calcd for $C_{15}H_{11}ClN_2$: C, 70.73; H, 4.35; N, 11.00; Found: C, 70.64; H, 4.37; N, 11.06;

3-(1-(4-chlorophenyl)vinyl)-8-methylimidazo[1,2-a]pyridine(3m): 1H NMR (400 MHz, $CDCl_3$): δ 7.65 (s, 1H), 7.50 (d, $J = 7.2$ Hz, 1H), 7.32 (d, $J = 8.8$ Hz, 2H), 7.24 (d, $J = 8.8$ Hz, 2H), 6.98 (d, $J = 6.8$ Hz, 1H), 6.61 (d, $J = 6.8$ Hz, 1H), 5.73 (s, 1H), 5.60 (s, 1H), 2.16 (s, 3H). ^{13}C NMR (100 MHz,

CDCl₃): δ 146.7, 137.0, 136.6, 134.5, 133.5, 129.0, 128.3, 127.7, 123.3, 122.7, 117.4, 112.4, 17.0. ESI-MS m/z (%) 269(100) [M+H]⁺. Anal. Calcd for C₁₆H₁₃ClN₂:C, 71.51; H, 4.88; N, 10.42; Found: C, 71.59; H, 4.90; N, 10.35;

3-(1-(4-chlorophenyl)vinyl)-7-methylimidazo[1,2-a]pyridine(3n): ¹H NMR (400 MHz, CDCl₃): δ 7.63 (s, 1H), 7.50 (d, J = 7.2 Hz, 2H), 7.32 (d, J = 8.8 Hz, 2H), 7.24 (d, J = 8.8 Hz, 2H), 6.55 (d, J = 6.8 Hz, 1H), 5.70 (s, 1H), 5.59 (s, 1H), 2.38 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 146.4, 136.9, 136.2, 134.6, 133.4, 129.4, 129.0, 128.8, 128.3, 124.1, 116.2, 115.4, 21.2. ESI-MS m/z (%) 269(100) [M+H]⁺. Anal. Calcd for C₁₆H₁₃ClN₂:C, 71.51; H, 4.88; N, 10.42; Found: C, 71.60; H, 4.85; N, 10.37;

2-methyl-3-(1-phenylvinyl)imidazo[1,2-a]pyridine(3o): ¹H NMR (400 MHz, CDCl₃): δ 7.66 (s, J = 9.2 Hz, 1H), 7.50 (d, J = 6.8 Hz, 1H), 7.24-7.33 (m, 5H), 7.12 (t, J = 6.8 Hz, 1H), 6.59 (t, J = 6.8 Hz, 1H), 5.98 (s, 1H), 5.49 (s, 1H), 2.45 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 144.5, 144.2, 138.3, 137.2, 128.9, 128.5, 126.5, 124.5, 124.1, 119.0, 116.6, 111.6, 14.0. ESI-MS m/z (%) 235(100) [M+H]⁺. Anal. Calcd for C₁₆H₁₄N₂:C, 82.02; H, 6.02; N, 11.96; Found: C, 82.15; H, 5.99; N, 11.90;

2,7-dimethyl-3-(1-phenylvinyl)imidazo[1,2-a]pyridine(3p): ¹H NMR (400 MHz, CDCl₃): δ 7.24-7.37 (m, 7H), 6.41 (t, J = 6.8 Hz, 1H), 5.94 (s, 1H), 5.47 (s, 1H), 2.42 (s, 3H), 2.34 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 144.9, 144.2, 138.5, 137.3, 135.2, 128.8, 128.5, 126.6, 123.8, 118.6, 115.1, 114.3, 21.2, 13.9. ESI-MS m/z (%) 249 (100) [M+H]⁺. Anal. Calcd for C₁₇H₁₆N₂:C, 82.22; H, 6.49; N, 11.28; Found: C, 82.10; H, 5.96; N, 11.37;

2,8-dimethyl-3-(1-phenylvinyl)imidazo[1,2-a]pyridine(3q): ¹H NMR (400 MHz, CDCl₃): δ 7.23-7.39 (m, 6H), 6.91 (d, J = 7.2 Hz, 1H), 6.50 (t, J = 6.8 Hz, 1H), 5.98 (s, 1H), 5.48 (s, 1H), 2.62 (s, 3H), 2.47 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 144.9, 141.7, 138.4, 137.5, 128.8, 128.4, 126.5, 126.3, 123.1, 122.5, 119.0, 111.6, 17.1, 14.0. ESI-MS m/z (%) 249 (100) [M+H]⁺. Anal. Calcd for C₁₇H₁₆N₂:C, 82.22; H, 6.49; N, 11.28; Found: C, 82.15; H, 5.99; N, 11.32;

2-phenyl-3-(1-phenylvinyl)imidazo[1,2-a]pyridine(3r): ¹H NMR (400 MHz, CDCl₃): δ 7.92-7.95 (m, 2H), 7.63-7.70 (m, 2H), 7.31-7.39 (m, 7H), 7.12-7.19 (m, 2H), 6.67 (d, J = 6.8 Hz, 1H), 6.16 (s, 1H), 5.57 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 137.6, 132.2, 129.0, 128.8, 128.7, 128.6, 128.5, 128.3, 127.9, 127.6, 127.2, 126.2, 124.7, 121.4, 117.3, 112.2. ESI-MS m/z (%) 249 (100) [M+H]⁺. Anal. Calcd for C₂₁H₁₆N₂:C, 85.11; H, 6.44; N, 9.45; Found: C, 85.00; H, 6.47; N, 9.51;

(2E)-butyl 3-(2-methyl-imidazo[1,2-a]pyridin-3-yl)acrylate (4a): ¹H NMR (400 MHz, CDCl₃): δ 8.31 (d, J = 6.8 Hz, 1H), 7.95 (d, J = 16.1 Hz, 1H), 7.61 (d, J = 8.9 Hz, 1H), 7.29 (d, J = 9.7 Hz, 1H), 6.96 (s, 1H), 6.24 (d, J = 16.1 Hz, 1H), 4.25 (s, 2H), 2.63 (s, 3H), 1.76 – 1.67 (m, 2H), 1.51 – 1.42 (m, 2H), 0.98 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 167.7, 146.4, 129.0, 126.2, 124.3, 117.4, 113.5, 112.8, 64.5, 39.9, 19.2, 15.6, 13.8. ESI-MS m/z (%) 259 (100) [M+H]⁺. Calcd for C₁₅H₁₈N₂O₂: C, 69.74; H, 7.02; N, 10.84; Found: C, 69.63; H, 7.05; N, 10.90;

(2E)-methyl 3-(2-methyl-imidazo[1,2-a]pyridin-3-yl)acrylate (4b): ¹H NMR (400 MHz, CDCl₃): δ 8.31 (d, J = 6.8 Hz, 1H), 7.95 (d, J = 16.1 Hz, 1H), 7.62 (d, J = 9.0 Hz, 1H), 7.34 – 7.29 (m, 1H), 6.97 (t, J = 6.8 Hz, 1H), 6.24 (d, J = 16.1 Hz, 1H), 3.84 (s, 3H), 2.63 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 168.1, 146.2, 129.2, 126.3, 124.3, 117.4, 113.6, 112.3, 51.8, 15.7. ESI-MS m/z (%) 217 (100) [M+H]⁺. Calcd for C₁₂H₁₂N₂O₂: C, 66.65; H, 5.59; N, 12.96; Found: C, 66.56; H, 5.56; N, 13.04;

(2E)-ethyl 3-(2-methyl-imidazo[1,2-a]pyridin-3-yl)acrylate (4c): ^1H NMR (400 MHz, CDCl_3): δ 8.34 (d, J = 6.8 Hz, 1H), 7.97 (d, J = 16.1 Hz, 1H), 7.65 (d, J = 8.9 Hz, 1H), 7.36 – 7.31 (m, 1H), 6.99 (t, J = 6.8 Hz, 1H), 6.26 (d, J = 16.1 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 2.66 (s, 3H), 1.38 (t, J = 7.1 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 167.6, 146.3, 129.0, 126.4, 124.3, 117.4, 113.7, 113.1, 60.6, 15.6, 14.4. MS (EI) m/z (%): 230, 185, 158, 78, 51; ESI-MS m/z (%) 231 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{13}\text{H}_{14}\text{N}_2\text{O}_2$: C, 67.81; H, 6.13; N, 12.17; Found: C, 67.95; H, 5.52; N, 12.97;

(2E)-butyl 3-(2,5-dimethyl-imidazo[1,2-a]pyridin-3-yl)acrylate(4d): ^1H NMR (400 MHz, CDCl_3): δ 8.09 (s, 1H), 7.91 (d, J = 16.1 Hz, 1H), 7.55 (d, J = 9.0 Hz, 1H), 7.16 (d, J = 9.0 Hz, 1H), 6.22 (d, J = 16.1 Hz, 1H), 4.25 (t, J = 6.7 Hz, 2H), 2.59 (s, 3H), 2.39 (s, 3H), 1.76 – 1.69 (m, 2H), 1.51 – 1.42 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 167.8, 129.4, 129.0, 123.6, 122.2, 116.4, 112.5, 76.8, 64.4, 30.8, 19.2, 18.3, 15.3, 13.7. ESI-MS m/z (%) 273 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{16}\text{H}_{20}\text{N}_2\text{O}_2$: C, 70.56; H, 7.40; N, 10.29; Found: C, 70.42; H, 7.44; N, 10.35;

(2E)-methyl 3-(2,5-dimethyl-imidazo[1,2-a]pyridin-3-yl)acrylate (4e): ^1H NMR (400 MHz, CDCl_3): δ 8.06 (s, 1H), 7.90 (d, J = 16.1 Hz, 1H), 7.52 (d, J = 9.1 Hz, 1H), 7.15 (d, J = 9.0 Hz, 1H), 6.20 (d, J = 16.1 Hz, 1H), 3.82 (s, 3H), 2.57 (s, 3H), 2.37 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 168.1, 145.3, 129.5, 129.3, 123.6, 122.2, 116.5, 112.0, 77.4, 77.1, 76.8, 51.7, 18.4, 15.4. ESI-MS m/z (%) 231 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{13}\text{H}_{14}\text{N}_2\text{O}_2$: C, 67.81; H, 6.13; N, 12.17; Found: C, 67.70; H, 6.16; N, 12.24;

(2E)-ethyl 3-(2,5-dimethyl-imidazo[1,2-a]pyridin-3-yl)acrylate (4f): ^1H NMR (400 MHz, CDCl_3): δ 8.06 (s, 1H), 7.89 (d, J = 16.1 Hz, 1H), 7.48 (d, J = 9.1 Hz, 1H), 7.13 (q, J = 9.0 Hz, 1H), 6.19 (d, J = 16.1 Hz, 1H), 4.28 (q, J = 7.1 Hz, 2H), 2.57 (s, 3H), 2.37 (s, 3H), 1.35 (t, J = 7.1 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 167.7, 129.3, 129.1, 123.5, 122.3, 116.5, 112.3, 60.5 (J = 36.4), 18.4, 15.6, 14.4. ESI-MS m/z (%) 245 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_2$: C, 68.83; H, 6.60; N, 11.47; Found: C, 68.70; H, 6.64; N, 11.54;

(2E)-butyl 3-(2,8-dimethyl-imidazo[1,2-a]pyridin-3-yl)acrylate (4g): ^1H NMR (400 MHz, CDCl_3): δ 8.16 (d, J = 6.8 Hz, 1H), 7.92 (d, J = 16.1 Hz, 1H), 7.09 (d, J = 6.9 Hz, 1H), 6.85 (t, J = 6.9 Hz, 1H), 6.21 (d, J = 16.1 Hz, 1H), 4.22 (t, J = 6.7 Hz, 2H), 2.62 (d, J = 9.8 Hz, 6H), 1.74 – 1.66 (m, 2H), 1.44 (q, J = 7.5 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 167.8, 148.1, 146.7, 129.3, 127.3, 125.4, 122.2, 118.2, 113.5, 112.5, 64.5, 30.9, 19.2, 17.0, 15.6, 13.8. MS (EI) m/z (%): 280, 272, 199, 172, 159, 146, 103, 92, 63. ESI-MS m/z (%) 273 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{16}\text{H}_{20}\text{N}_2\text{O}_2$: C, 70.56; H, 7.04; N, 10.29; Found: C, 70.42; H, 7.07; N, 10.36;

(2E)-ethyl 3-(2,8-dimethyl-imidazo[1,2-a]pyridin-3-yl)acrylate(4h): ^1H NMR (400 MHz, CDCl_3): δ 8.17 (d, J = 6.8 Hz, 1H), 7.93 (d, J = 16.1 Hz, 1H), 7.10 (d, J = 6.8 Hz, 1H), 6.86 (t, J = 6.9 Hz, 1H), 6.22 (d, J = 16.1 Hz, 1H), 4.29 (q, J = 7.1 Hz, 2H), 2.62 (d, J = 10.2 Hz, 6H), 1.36 (t, J = 7.1 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 167.7, 148.0, 146.6, 129.3, 127.3, 125.4, 122.1, 118.1, 113.5, 112.6, 60.5, 17.0, 15.6, 14.4. MS (EI) m/z (%): 244, 213, 207, 199, 197, 172, 169, 146, 102, 92, 85, 63; ESI-MS m/z (%) 245 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_2$: C, 68.83; H, 6.60; N, 11.47; Found: C, 68.72; H, 6.62; N, 11.54;

(2E)-butyl 3-(2,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)acrylate(4i):

¹H NMR (400 MHz, CDCl₃): δ 8.19 (d, *J* = 7.0 Hz, 1H), 7.91 (d, *J* = 16.1 Hz, 1H), 7.37 (s, 1H), 6.79 (d, *J* = 7.0 Hz, 1H), 6.18 (d, *J* = 16.1 Hz, 1H), 4.24 (t, *J* = 6.7 Hz, 2H), 2.60 (s, 3H), 2.44 (s, 3H), 1.71 (dt, *J* = 14.6, 6.8 Hz, 2H), 1.46 (q, *J* = 7.5 Hz, 2H), 0.98 (q, *J* = 5.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 167.9, 149.0, 146.9, 137.7, 129.1, 123.7, 116.1, 116.0, 111.6, 64.4, 30.9, 21.3, 19.2, 15.4, 13.8. ESI-MS *m/z* (%) 273 (100) [M+H]⁺. Calcd for C₁₆H₂₀N₂O₂: C, 70.56; H, 7.40; N, 10.29; Found: C, 70.42; H, 7.43; N, 10.36;

Ethyl 3-((*E*)-2-(butoxycarbonyl)vinyl)-imidazo[1,2-*a*]pyridine-2-carboxylate(4j): ¹H NMR (400 MHz, CDCl₃): δ 8.48 – 8.37 (m, 2H), 7.78 (d, *J* = 9.1 Hz, 1H), 7.41 – 7.35 (m, 1H), 7.04 (t, *J* = 6.9 Hz, 1H), 6.75 (d, *J* = 16.6 Hz, 1H), 4.50 (q, *J* = 7.1 Hz, 2H), 4.24 (t, *J* = 6.7 Hz, 2H), 1.75 – 1.65 (m, 2H), 1.48 – 1.41 (m, 5H), 0.96 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 166.9, 163.1, 146.0, 137.3, 129.1, 127.4, 125.3, 119.6, 119.4, 118.1, 64.8, 61.6, 30.7, 19.1, 14.3, 13.7. ESI-MS *m/z* (%) 317 (100) [M+H]⁺. Calcd for C₁₇H₂₀N₂O₄: C, 64.54; H, 6.37; N, 8.86; Found: C, 64.67; H, 6.39; N, 8.80;

(2*E*)-methyl 3-(7-methyl-imidazo[1,2-*a*]pyridin-3-yl)acrylate(4k):

¹H NMR (400 MHz, CDCl₃): δ 8.22 (d, *J* = 6.8 Hz, 1H), 7.99 (s, 1H), 7.89 (d, *J* = 16 Hz, 1H), 7.48 (s, 1H), 6.86 (d, *J* = 6.8 Hz, 1H), 6.38 (d, *J* = 16 Hz, 1H), 3.84 (s, 3H), 2.47 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 167.6, 137.7, 137.2, 128.9, 123.4, 117.1, 116.6, 112.8, 51.8, 21.3. ESI-MS *m/z* (%) 217 (100) [M+H]⁺. Calcd for C₁₂H₁₂N₂O₂: C, 66.65; H, 5.59; N, 12.96; Found: C, 66.54; H, 5.62; N, 13.02;

(2*E*)-ethyl 3-(7-methyl-imidazo[1,2-*a*]pyridin-3-yl)acrylate (4l): ¹H NMR (400 MHz, CDCl₃): δ 8.22 (d, *J* = 6.8 Hz, 1H), 7.98 (s, 1H), 7.88 (d, *J* = 16 Hz, 1H), 7.47 (s, 1H), 6.85 (d, *J* = 7.2 Hz, 1H), 6.38 (d, *J* = 16 Hz, 1H), 4.32 (q, *J* = 7.2 Hz, 2H), 2.46 (s, 3H), 2.47 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 167.3, 137.6, 137.3, 128.7, 123.5, 117.0, 116.6, 113.2, 60.6, 21.3, 14.4. ESI-MS *m/z* (%) 231 (100) [M+H]⁺. Calcd for C₁₃H₁₄N₂O₂: C, 67.81; H, 6.13; N, 12.17; Found: C, 67.70; H, 6.16; N, 12.23;

(2*E*)-methyl 3-(8-methyl-imidazo[1,2-*a*]pyridin-3-yl)acrylate(4m): ¹H NMR (400 MHz, CDCl₃): δ 8.19 (d, *J* = 6.8 Hz, 1H), 8.07 (s, 1H), 7.87 (d, *J* = 15.9 Hz, 1H), 7.15 (d, *J* = 6.8 Hz, 1H), 6.93 (t, *J* = 6.8 Hz, 1H), 6.42 (d, *J* = 15.9 Hz, 1H), 3.83 (s, 3H), 2.63 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 167.7, 135.6, 128.8, 128.3, 125.7, 121.9, 114.2, 114.1, 51.8, 20.9, 16.9. ESI-MS *m/z* (%) 217 (100) [M+H]⁺. Calcd for C₁₂H₁₂N₂O₂: C, 66.65; H, 5.59; N, 12.96; Found: C, 66.52; H, 5.61; N, 13.04;



(2*E*)-ethyl 3-(8-methyl-imidazo[1,2-*a*]pyridin-3-yl)acrylate(4l): ¹H NMR (400 MHz, CDCl₃): δ 8.19 (d, *J* = 6.7 Hz, 1H), 8.02 (s, 1H), 7.87 (d, *J* = 15.9 Hz, 1H), 7.13 (d, *J* = 6.8 Hz, 1H), 6.91 (t, *J* = 6.9 Hz, 1H), 6.40 (d, *J* = 15.9 Hz, 1H), 4.32 – 4.26 (m, 2H), 2.64 (s, 3H), 1.35 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 167.2, 136.2, 128.8, 128.4, 125.2, 122.0, 114.7, 114.0, 60.6, 16.9, 14.4. ESI-MS *m/z* (%) 231 (100) [M+H]⁺. Calcd for C₁₃H₁₄N₂O₂: C, 67.81; H, 6.13; N, 12.17; Found: C, 67.68; H, 6.17; N, 12.26;

(2*E*)-butyl 3-(6-methyl-imidazo[1,2-*a*]pyridin-3-yl)acrylate(4o): ¹H NMR (400 MHz, CDCl₃): δ 8.07 (s, 1H), 7.96 (s, 1H), 7.83 (d, *J* = 15.9 Hz, 1H), 7.57 (d, *J* = 9.1 Hz, 1H), 7.14 (d, *J* = 9.1 Hz, 1H), 6.36 (d, *J* = 15.9 Hz, 1H), 4.21 (t, *J* = 6.7 Hz, 2H), 2.38 (s, 3H), 1.72 – 1.65 (m, 2H), 1.43 (q, *J* = 7.4 Hz, 2H), 0.95 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 167.45, 136.86, 129.21, 128.65, 123.86, 122.02, 117.70, 113.69, 64.53, 30.84, 19.22, 18.40, 13.77. MS (EI) *m/z* (%): 258, 202, 185, 158, 145, 92, 77, 51; ESI-MS *m/z* (%) 259 (100) [M+H]⁺. Calcd for C₁₅H₁₈N₂O₂: C, 69.74; H, 7.02; N, 10.84;



Found: C, 69.62; H, 7.02; N, 10.91;

(2E)-methyl 3-(6-methyl-imidazo[1,2-a]pyridin-3-yl)acrylate(4p): ^1H NMR (400 MHz, CDCl_3): δ 8.11 (s, 1H), 8.02 (s, 1H), 7.86 (d, $J = 15.9$ Hz, 1H), 7.69 (d, $J = 9.0$ Hz, 1H), 7.21 (d, $J = 8.7$ Hz, 1H), 6.40 (d, $J = 15.9$ Hz, 1H), 3.84 (s, 3H), 2.41 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 167.7, 136.0, 129.8, 128.7, 124.3, 122.0, 117.5, 113.8, 51.9, 18.4. ESI-MS m/z (%) 217 (100) $[\text{M}+\text{H}]^+$. Calcd for $\text{C}_{12}\text{H}_{12}\text{N}_2\text{O}_2$: C, 66.65; H, 5.59; N, 12.96; Found: C, 66.74; H, 5.55; N, 12.88;


3a




3b




3c




3d




3e




3f




3g





3h









3j





3k








3m




3n







3p




3q




3r





4a




4b




4c




4d




4e




4f




4g




4h








4j




4k







4m



4n





The figure displays the ^1H and ^{13}C NMR spectra of compound 10, which is 2-(4-methyl-1H-benzimidazol-2-yl)-3-methoxyacrylate. The chemical structure is shown in the top right corner.

^1H NMR Spectrum (Top): The spectrum shows peaks in the aromatic region (7.0–8.1 ppm) and aliphatic region (2.4–3.9 ppm). The peak at 0.0 ppm is the TMS reference. Integration values are provided below the peaks.

Chemical Shift (ppm)	Integration
8.107	0.01
8.017	0.01
7.883	0.01
7.844	0.01
7.260	0.01
7.223	0.01
7.202	0.01
6.420	0.01
6.360	0.01
3.896	0.01
2.413	0.01
0.0	0.01

^{13}C NMR Spectrum (Bottom): The spectrum shows peaks in the aromatic region (113–168 ppm) and aliphatic region (18–52 ppm). The peak at 0.0 ppm is the TMS reference.

Chemical Shift (ppm)
167.660
136.036
129.764
128.672
124.306
122.004
117.514
113.844
51.860
18.425
0.0

